T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT)

What is the purpose of this trial?

The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.

Participation Guidelines

Ages: 18 - 45 years

Gender: Both

University of California, San Francisco

Start Date: 05/25/2017

End Date: 07/31/2021

Last Updated: 02/22/2018

Study HIC#: 1607018090

Get Involved

For more information about this study, contact:
Linda Ryall
+1 203-737-4510

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Kevan Herold

Principal Investigator